AVP-13358 is an orally active IgE inhibitor that effectively suppresses immunoglobulin E (IgE)-mediated immune responses, with IC50 values of 8 nM and 3 nM in vivo and in vitro in BALB/c mice, respectively; it directly acts on T cells to inhibit the production and release of IL-4, IL-5, and IL-13; it also targets and inhibits other key markers involved in allergic responses, including the B-cell IgE receptor (CD23) in human monocytes and CD23 and IL-4 receptor in murine B cells; it is used in research on anti-allergic responses.